A Timeline From Index Procedure To Complex Reinterventions For Thoracoabdominal Aortic Dissection.

The optimal management of acute type A aortic dissection (ATAAD) remains a controversial subject. While some surgeons opt for a hemiarch approach to minimize bypass and cross-clamping time, others prefer partial or total arch replacement to prevent the need for additional operations. The advent of hybrid approaches offers a variety of options to the aortic surgeon in treating ATAAD.

Arthrodesis or Open Reduction Internal Fixation for Lisfranc Injuries: A Meta-analysis.

The purpose of this study is to determine if arthrodesis, compared with open reduction and internal fixation (ORIF), produces favorable American Orthopaedic Foot and Ankle Society (AOFAS) and visual analogue scale (VAS) scores, and to determine if differences in complication, revision surgery, and secondary arthrodesis rates exist for patients with Lisfranc fracture/dislocation injuries. Searches were performed in PubMed using the keywords "Lisfranc fracture," "metatarsal fracture," "ORIF," "open reduction internal fixation," "arthrodesis," and "fusion." These criteria left 183 articles for review.

Health IT, hacking, and cybersecurity: national trends in data breaches of protected health information.

Objective: The rapid adoption of health information technology (IT) coupled with growing reports of ransomware, and hacking has made cybersecurity a priority in health care. This study leverages federal data in order to better understand current cybersecurity threats in the context of health IT.

Materials And Methods: Retrospective observational study of all available reported data breaches in the United States from 2013 to 2017, downloaded from a publicly available federal regulatory database.

Crystal structure of {()--[(benzo[]quinolin-2-yl)meth-yl]--[(benzo[]quinolin-2-yl)methyl-idene]-1,1'-binaphthyl-2,2'-di-amine-κ,','','''}(trifluoromethane-sulfonato-κ)zinc(II)} trifluoromethane-sulfonate di-chloro-methane 1.5-solvate.

The zinc(II) atom in the title compound, [Zn(CHN)(CFSO)](CFSO)·1.5CHCl, adopts a distorted five-coordinate square-pyramidal geometry. It is coordinated by one tri-fluoro-methane-sulfonate ligand and four N atoms of the -[(benzo[]quinolin-2-yl)meth-yl]--[(benzo[]quinolin-2-yl)methyl-idene]-1,1'-binaphthyl-2,2'-di-amine ligand.

Crystal structure of ({(1,2)-,'-bis-[(quino-lin-2-yl)methyl]cyclo-hexane-1,2-di-amine}-chlorido-iron(III))-μ-oxido-[tri-chlorido-ferrate(III)] chloro-form monosolvate.

The first Fe atom in the solvated title compound, [FeClO(CHN)]·CHCl, adopts a distorted six-coordinate octa-hedral geometry. It is coordinated by one chloride ligand, four N atoms from the (1,2)-,'-bis-[(quinolin-2-yl)methyl]cyclo-hexane-1,2-di-amine ligand, and a bridging oxido ligand attached to the second Fe atom, which is also bonded to three chloride ions. A very weak intra-molecular N-H⋯Cl hydrogen bond occurs.

Mono- and dinuclear nickel(II) complexes of resolved Schiff-base ligands with extended quinoline substituents.

The coordination chemistry of four enantiopure tetradentate bis(iminoquinoline) ligands with nickel(II) salts is reported. The previously reported ligands CBQ, CPQ, BBQ, and BPQ result from the condensation of (1R,2R)-cyclohexyldiamine or (R)-BINAM with two equivalents of 2-formylbenzo[h]quinoline or 8-isopropyl-2-quinolinecarboxaldehyde {CBQ = (1R,2R)-cyclohexanediamine-N,N'-bis(benzo[h]quinoline-2-ylmethylene), CPQ = (1R,2R)-cyclohexanediamine-N,N'-bis[[(8-isopropyl)-2-quinolinyl]methylene], BBQ = [(R)-1,1'-binaphthalene]-2,2'-diamine-N,N'-bis(benzo[h]quinoline-2-ylmethylene), BPQ = [(R)-1,1'-binaphthalene]-2,2'-diamine-N,N'-bis[[(8-isopropyl)-2-quinolinyl]methylene]}. Reaction of NiI(2) with the (1R,2R)-cyclohexyl ligands gives the mononuclear distorted trigonal-bipyramidal (TBP) complexes [Ni(N(3)-CBQ)I(2)] and [Ni(N(3)-CPQ)I(2)].

Practice standards for transcranial Doppler (TCD) ultrasound. Part II. Clinical indications and expected outcomes.

Introduction: Transcranial Doppler (TCD) is a physiological ultrasound test with established safety and efficacy. Although imaging devices may be used to depict intracranial flow superimposed on structural visualization, the end-result provided by imaging duplex or nonimaging TCD is sampling physiological flow variables through the spectral waveform assessment.

Summary Of Results: Clinical indications considered by this multidisciplinary panel of experts as established are: sickle cell disease, cerebral ischemia, detection of right-to-left shunts (RLS), subarachnoid hemorrhage, brain death, and periprocedural or surgical monitoring.

Double-stranded monohelical complexes from an unsymmetrical chiral Schiff-base ligand.

A new Schiff-base ligand is prepared by a two-step reaction of 3-formylsalicylic acid and (1R, 2R)-diaminocyclohexane in alcoholic solvents. The 1:1 condensation product exists as a zwitterion in the solid state and forms pleated hydrogen-bonded sheets. Metalation of the ligand with divalent iron, nickel, cobalt, and zinc resulted in the formation of double-stranded monohelices with exclusively M-helicity.

Dinuclear zinc(II) complexes of symmetric Schiff-base ligands with extended quinoline sidearms.

The synthesis of two 2-formylquinolines is reported via the Skraup method followed by SeO(2) oxidation. Each aldehyde is condensed with (1R,2R)-diaminocyclohexane and (R)-BINAM, yielding four enantiomerically-pure bis(imine-quinoline) ligands. The neutral ligands are reacted with ZnCl(2) to give complexes with bis(bidentate) coordination of ZnCl(2) units.

Iron(II) and zinc(II) monohelical binaphthyl-salen complexes with overlapping benz[a]anthryl sidearms.

The synthesis of the polyaromatic aldehyde 1-hydroxybenz[a]anthracene-2-carboxaldehyde is reported via a seven step protocol from 9,10-dihydroanthracene, with an overall yield of 30%. Two equivalents of the aldehyde are condensed with (R)-1,1'-binaphthyl-2,2'-diamine to produce a new binaphthyl-salen ligand, which is subsequently complexed to iron(II) and zinc(II) ions. The ligand and complexes are characterized by single-crystal X-ray crystallography.

Monohelical Iron(II) and Zinc(II) complexes of a (1R,2R)-cyclohexyl salen ligand with benz[a]anthryl sidearms.

An enantiomerically pure C2-symmetric salen ligand with benz[a]anthracene siderams produces M helical complexes (FeII and ZnII) in solution. Interconversion to produce a 1:1 mixture of helical conformers in the solid state is possible, despite overlapped sidearms.

Iron(II) and zinc(II) monohelical binaphthyl salen complexes.

A new chiral binaphthyl salen ligand with rigid polyaromatic sidearms gives monohelical complexes (Fe(II) and Zn(II)) of predetermined handedness.

Kinetic resolution of chiral alpha-olefins using optically active ansa-zirconocene polymerization catalysts.

A series of enantiopure C1-symmetric metallocenes, [(SiMe2)2[eta5-C5H(CHMe2)2][eta5-C5H2((S)-CHMeCMe3)]]ZrCl2, (S)-2, [(SiMe2)2[eta5-C5H(CHEt2)2][eta5-C5H2((S)-CHMeCMe3)]]ZrCl2, (S)-6, and [(SiMe2)2[eta5-C5HCy2][eta5-C5H2((S)-CHMeCMe3)]]ZrCl2, (S)-7 (Cy = cyclohexyl), zirconocene dichlorides that have an enantiopure methylneopentyl substituent on the "upper" cyclopentadienyl ligand, and diastereomerically pure precatalysts, [(SiMe2)2[eta5-C5H((S)-CHMeCy)(CHMe2)][eta5-C5H3]]ZrCl2, (S)-8a and (S)-8b, which have an enantiopure, 1-cyclohexylethyl substituent on the "lower" cyclopentadienyl ligand, has been synthesized for use in the polymerization of chiral alpha-olefins. When activated with methylaluminoxane, these metallocenes show unprecedented activity for the polymerization of bulky racemic monomers bearing substitution at the 3- and/or 4-positions. Due to the optically pure nature of these single site catalysts, they effect kinetic resolution of racemic monomers: the polymeric product is enriched with the faster reacting enantiomer, while recovered monomer is enriched with the slower reacting enantiomer.

The use of complementary and alternative therapies by people with multiple sclerosis.

Complementary and alternative medicine (CAM) refers to therapeutic approaches not considered part of conventional medicine. A survey was mailed to sample of patients with multiple sclerosis (MS). The response rate was 440/673 (65%).